BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BIO.B - US0905721082 - Common Stock
310.7 USD
-3.7 (-1.18%)
Taking everything into account, BIO.B scores 4 out of 10 in our fundamental rating. BIO.B was compared to 57 industry peers in the Life Sciences Tools & Services industry. While BIO.B has a great health rating, its profitability is only average at the moment. BIO.B is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BIO.B had positive earnings in the past year.
BIO.B had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIO.B reported negative net income in multiple years.
BIO.B had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BIO.B has a Return On Assets (-6.97%) which is comparable to the rest of the industry.
With a Return On Equity value of -10.03%, BIO.B perfoms like the industry average, outperforming 53.45% of the companies in the same industry.
BIO.B has a Return On Invested Capital of 2.26%. This is in the better half of the industry: BIO.B outperforms 62.07% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIO.B is significantly below the industry average of 13.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
The Operating Margin of BIO.B (10.27%) is better than 70.69% of its industry peers.
BIO.B's Operating Margin has been stable in the last couple of years.
With a decent Gross Margin value of 52.42%, BIO.B is doing good in the industry, outperforming 63.79% of the companies in the same industry.
BIO.B's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
BIO.B has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BIO.B has less shares outstanding
Compared to 5 years ago, BIO.B has less shares outstanding
BIO.B has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.42 indicates that BIO.B is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.42, BIO.B is in the better half of the industry, outperforming 62.07% of the companies in the same industry.
BIO.B has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO.B would need 3.57 years to pay back of all of its debts.
BIO.B's Debt to FCF ratio of 3.57 is fine compared to the rest of the industry. BIO.B outperforms 77.59% of its industry peers.
BIO.B has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
BIO.B's Debt to Equity ratio of 0.18 is in line compared to the rest of the industry. BIO.B outperforms 56.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.42 |
ROIC/WACC0.23
WACC9.97%
2.3 Liquidity
A Current Ratio of 5.44 indicates that BIO.B has no problem at all paying its short term obligations.
BIO.B's Current ratio of 5.44 is amongst the best of the industry. BIO.B outperforms 86.21% of its industry peers.
A Quick Ratio of 3.94 indicates that BIO.B has no problem at all paying its short term obligations.
BIO.B has a Quick ratio of 3.94. This is in the better half of the industry: BIO.B outperforms 70.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
BIO.B shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.90%.
BIO.B shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.84% yearly.
Looking at the last year, BIO.B shows a decrease in Revenue. The Revenue has decreased by -0.88% in the last year.
The Revenue has been growing slightly by 2.11% on average over the past years.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
BIO.B is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.66% yearly.
BIO.B is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.26% yearly.
EPS Next Y-1.94%
EPS Next 2Y0.36%
EPS Next 3Y3.89%
EPS Next 5Y-2.66%
Revenue Next Year0.31%
Revenue Next 2Y1.3%
Revenue Next 3Y2.08%
Revenue Next 5Y1.26%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 30.14 indicates a quite expensive valuation of BIO.B.
BIO.B's Price/Earnings ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 70.69% of the companies in the same industry.
When comparing the Price/Earnings ratio of BIO.B to the average of the S&P500 Index (27.30), we can say BIO.B is valued inline with the index average.
With a Price/Forward Earnings ratio of 29.92, BIO.B can be considered very expensive at the moment.
BIO.B's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 68.97% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BIO.B to the average of the S&P500 Index (24.04), we can say BIO.B is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.14 | ||
| Fwd PE | 29.92 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO.B is valued a bit cheaper than the industry average as 79.31% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.89 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.85
EPS Next 2Y0.36%
EPS Next 3Y3.89%
5. Dividend
5.1 Amount
BIO.B does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BIO.B (11/17/2025, 8:04:00 PM)
310.7
-3.7 (-1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.44%
Inst Owner Change0%
Ins Owners8.18%
Ins Owner ChangeN/A
Market Cap8.38B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target363.55 (17.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)-1.58%
PT rev (3m)-1.58%
EPS NQ rev (1m)-2.73%
EPS NQ rev (3m)2.57%
EPS NY rev (1m)-0.35%
EPS NY rev (3m)18.63%
Revenue NQ rev (1m)-1.14%
Revenue NQ rev (3m)2.24%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)2.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.14 | ||
| Fwd PE | 29.92 | ||
| P/S | 3.28 | ||
| P/FCF | 24.89 | ||
| P/OCF | 17.05 | ||
| P/B | 1.24 | ||
| P/tB | 1.45 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.32%
EPS(NY)10.38
Fwd EY3.34%
FCF(TTM)12.48
FCFY4.02%
OCF(TTM)18.22
OCFY5.87%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)N/A
PEG (5Y)3.85
Graham Number240.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.42 |
F-Score5
WACC9.97%
ROIC/WACC0.23
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-1.94%
EPS Next 2Y0.36%
EPS Next 3Y3.89%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.31%
Revenue Next 2Y1.3%
Revenue Next 3Y2.08%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.67%
EBIT Next 3Y15.44%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.B.
Can you provide the valuation status for BIO-RAD LABORATORIES -CL B?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Overvalued.
How profitable is BIO-RAD LABORATORIES -CL B (BIO.B) stock?
BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 4 / 10.
How financially healthy is BIO-RAD LABORATORIES -CL B?
The financial health rating of BIO-RAD LABORATORIES -CL B (BIO.B) is 7 / 10.